Pay in 4 interest-free payments of $5.90 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Key results at 80 weeks: Participants on the 4 mg dose lost an average of 47.2 lbs (19.0%) Participants on the 12 mg dose lost an average of 70.3 lbs (28.3%) 45.3% of participants on the 12 mg dose achieved at least 30% weight loss a level historically associated with bariatric surgery outcomes The 4 mg dose showed a lower rate of discontinuation due to adverse events than even placebo In a study extension to 104 weeks, participants with a starting BMI of 35 or higher who received 12 mg lost up to an average of 85.0 lbs (30.3%)
Don't forget the essentials Our Ipamorelin 5 mg vial is the most selective GHRP (Growth Hormone Releasing Peptide) available in peptide research
All at meaningful, research-informed doses
Chapter 41
Range of motion expands
